ATE435032T1 - Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind - Google Patents

Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind

Info

Publication number
ATE435032T1
ATE435032T1 AT03791048T AT03791048T ATE435032T1 AT E435032 T1 ATE435032 T1 AT E435032T1 AT 03791048 T AT03791048 T AT 03791048T AT 03791048 T AT03791048 T AT 03791048T AT E435032 T1 ATE435032 T1 AT E435032T1
Authority
AT
Austria
Prior art keywords
antigen
yersinia
yersinia pestis
monoclonal antibodies
antibodies specific
Prior art date
Application number
AT03791048T
Other languages
English (en)
Inventor
James Hill
Ethel Diane Williamson
Richard William Titball
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Secr Defence filed Critical Secr Defence
Application granted granted Critical
Publication of ATE435032T1 publication Critical patent/ATE435032T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT03791048T 2002-08-31 2003-08-29 Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind ATE435032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220257.0A GB0220257D0 (en) 2002-08-31 2002-08-31 Vaccine
PCT/GB2003/003747 WO2004019980A1 (en) 2002-08-31 2003-08-29 Vaccine against yersinia comprising one or two antibodies, one specific for yersinia pestis f1-antigen and the other one for yersina pestis v-antigen

Publications (1)

Publication Number Publication Date
ATE435032T1 true ATE435032T1 (de) 2009-07-15

Family

ID=9943275

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791048T ATE435032T1 (de) 2002-08-31 2003-08-29 Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind

Country Status (9)

Country Link
US (1) US7572449B2 (de)
EP (1) EP1536833B1 (de)
JP (1) JP2006500386A (de)
AT (1) ATE435032T1 (de)
AU (1) AU2003260752A1 (de)
CA (1) CA2495833A1 (de)
DE (1) DE60328201D1 (de)
GB (1) GB0220257D0 (de)
WO (1) WO2004019980A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101337069B (zh) * 2005-11-25 2012-07-25 中国药品生物制品检定所 复合鼠疫疫苗及其制备方法
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US7815911B1 (en) * 2006-10-10 2010-10-19 University Of Kentucky Research Foundation Compositions and methods for treating Yersinia pestis infection
WO2010043046A1 (en) * 2008-10-16 2010-04-22 Mcmaster University Peptide inhibitors of type iii secretion
WO2010117455A2 (en) * 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque
CN117343170B (zh) * 2023-10-13 2024-04-05 青海省地方病预防控制所 用于检测鼠疫耶尔森菌的抗LcrV抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
DE69625802T2 (de) 1995-03-13 2003-11-13 The Secretary Of State For Defence, Salisbury Impfstoffe gegen die pest
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU5046700A (en) * 1999-05-28 2000-12-18 Jennifer Aldrich Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
US20050181063A1 (en) 2000-03-22 2005-08-18 Alpar Hazire O. Pharmaceutical composition for administration to mucosal surfaces

Also Published As

Publication number Publication date
AU2003260752A1 (en) 2004-03-19
US20060093609A1 (en) 2006-05-04
GB0220257D0 (en) 2002-10-09
EP1536833A1 (de) 2005-06-08
WO2004019980A1 (en) 2004-03-11
JP2006500386A (ja) 2006-01-05
DE60328201D1 (de) 2009-08-13
US7572449B2 (en) 2009-08-11
CA2495833A1 (en) 2004-03-11
EP1536833B1 (de) 2009-07-01

Similar Documents

Publication Publication Date Title
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
CY1118098T1 (el) Fc riib-ειδικα αντισωματα και μεθοδοι χρησης αυτων
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
MY185813A (en) Factor xi antibodies and methods of use
NO20052220L (no) Fremgangsmater for behandling av Alzheimers sykdom ved anvendelse av antistoffer rettet mot amyloid beta-peptid og preparater derav
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CR11243A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
AR083293A1 (es) Agentes de union a cd33
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
EA201790858A3 (ru) Лечение и профилактика амилоидоза
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2021004173A (es) Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
CY1126559T1 (el) Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης
EA200601386A1 (ru) ИММУНОГЛОБУЛИНЫ ПРОТИВ АНТИГЕНА EpCAM
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties